RESUMEN
<p><b>OBJECTIVE</b>To compare the efficacy of endocrine therapy with chemotherapy for bone metastasis of breast cancer.</p><p><b>METHODS</b>A total of 138 breast cancer patients with bone metastasis, but without visceral metastasis as retrospectively reviewed.</p><p><b>RESULTS</b>The response rates of endocrine therapy and chemotherapy as the first-line therapy were 35.4% and 31.7% (P = 0.687), and the total response rates were 27.1% and 25.0% (P = 0.690). The clinical benefit rates of endocrine therapy and chemotherapy as first-line were 43.9% and 36.6% (P = 0.437), as second-line were 47.8% and 24.2% (P = 0.033), in total treatments were 47.5% and 27.7% (P = 0.001). The median interval to treatment failure (TTF) was 5 months and 2 months (P < 0.001), and that to progression (TTP) was 5 and 2.5 months (P < 0.001) in endocrine therapy and chemotherapy group, respectively.</p><p><b>CONCLUSION</b>Endocrine therapy is superior to chemotherapy for bone metastasis of breast cancer.</p>